A clinical study or trial is a research study to answer specific questions about new therapies or new ways of using known treatments. Clinical studies/trials test potential treatments in human volunteers to see if they should be approved for wider use in the general population.

Why Participate in a Clinical Trial?
Participants in clinical trials can play a more active role in their own health care, gain access to new research treatments before they are widely available, and help others by contributing to medical research. (Find out more including answers to frequently asked questions in this Guide to Randomized Clinical Trials.)

Irritable Bowel Syndrome (IBS)

Participants Sought for Study of Linaclotide’s Effect on Bi-directional Brain and Gut Axis in IBS-C Patients

Adults with Gastroparesis Sought for a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy of Tradipitant in Relieving Symptoms 

Purpose of study:The purpose of this study is to evaluate the efficacy of tradipitant in relieving symptoms of nausea in patients with gastroparesis. Patients will undergo a 4-week screening phase, after which they will be given twice-daily tradipitant (or placebo) for a further 4-week treatment period.

Sponsor: Vanda Pharmaceuticals, Inc.

Study Population: Male and female patients ages 18 to 70 years with a history of moderate to severe nausea who meet all inclusion and exclusion criteria.

Phase: Phase 2

Contact: For more information visit www.gpvandastudy.com or call 202-734-3400. Be sure to refer to this study by its Clinicaltrials.gov identifier: NCT02970968.

Verified May 2018

Seeking Women Who are Breastfeeding or Pumping and are Taking Linaclotide for IBS-C or CIC

Purpose of study: This study will determine the amount of linaclotide in breast milk after once daily doses of the drug over 4 consecutive days.

Sponsor: Forest Laboratories

Participation: Eligible female patients currently taking linaclotide for constipation predominant irritable bowel syndrome (IBS-C) or chronic idiopathic constipation (CIC) who have been actively breastfeeding or pumping for at least 4 weeks.

Phase: Phase 1

Location: Iowa City, Iowa

Contacts: Sandra Beaird, Pharm.D. Phone: 1-800-678-1605, ext 66297; Be sure to refer to this study by its ClinicalTrials.gov identifier: NCT02220348

Verified May 2018


Short Bowel Syndrome (SBS)

Patients with SBS Sought for Long-term Study

Purpose of Study: This global clinical study has begun enrolling patients with short bowel syndrome (SBS) in order to provide additional long-term data on safety of teduglutide and on the natural history of SBS in patients in routine, real world settings. The information gathered is intended to assist health care providers in optimizing their clinical decisionmaking in managing SBS patients.

Enrollment will include SBS patients treated and not treated with teduglutide.

Sponsor: Shire

Study Population: Male and female patients of any age with a diagnosis of SBS, including those who have never taken teduglutide, as well those who have or are using teduglutide.

Study Follow-up Duration: 10 years

Contact: Email: This email address is being protected from spambots. You need JavaScript enabled to view it.; be sure to refer to this study by its ClinicalTrials.gov identifier: NCT01990040

Verified May 2018

Purpose of study: Registry to evaluate the long-term safety profile for patients with SBS who are treated with teduglutide in a routine clinical setting. 

Sponsor: Shire

Participation: SBS patients treated and not treated with teduglutide will be enrolled. All ages accepted. This is an observational study. Data will be collected during routine consultations and clinical staff will enter this information into a system baseline and approximately every 6 months following. Each patient will be followed for at least 10 years.

Contact: Shire contact This email address is being protected from spambots. You need JavaScript enabled to view it.. ClinicalTrials.gov identifier: NCT01990040

Added July 2018

Study of Oral Budesonide for Treatment of EoE

Purpose of Study: A Phase 3, randomized, double-blind, placebo-controlled trial to study safety and efficacy of the drug oral budesonide suspension (OBS) in adolescent and adult subjects (11 to 55 years of age, inclusive) with eosinophilic esophagitis (EoE), which involves a planned 3-6 week screening period, a 16 week treatment period, and a 4 week follow-up period.

Sponsor: Shire

Study Population: Male and female patients with EoE aged 11 to 55 who meet inclusion criteria.

Phase: Phase 3

Contact: Email: This email address is being protected from spambots. You need JavaScript enabled to view it.; be sure to refer to this study by its ClinicalTrials.gov identifier: NCT02605837

Verified May 2018

Top of Page


Research Awards
2018 Award Recipients
Amaranath Karunanayake, PhD
Katja Kovacic, MD
Cristina Martinez, PhD
Ans Pauwels, PhD
2013 Award Recipients
Enrico Corazziari, MD
Jan Tack, MD, PhD
Report from Gary Mawe, PhD: The Roles of Intestinal Nerves and Serotonin in Gut Function and Dysfunction
Ashley Blackshaw, PhD
Carlo Di Lorenzo, MD
Niranga Manjuri Devanarayana, MD
Report from Lukas Van Oudenhove, PhD: Solving the Biopsychosocial Puzzle in Functional Dyspepsia
Muriel Larauche, PhD
2011 Award Recipients
Report from Ronnie Fass, MD: Sleep and Gastroesophageal Reflux Disease (GERD)
Million Mulugeta, PhD
Adrian Miranda, MD
Samuel Nurko, MD
Sudarshan Jadcherla, MD
Shaman Rajindrajith, MD
2009 Award Recipients
Satish Rao, MD
Emeran Mayer, MD
Javier Santos, MD
Report from Martin Storr, MD, PhD: Functional Gastrointestinal Disorders: New Insights in Enteric Regulation
Report From Miguel Saps, MD: Functional Abdominal Pain in Children and Adolescents
2007 Award Recipients
Report from Bruce D. Naliboff, PhD: Symptom Based Psychology for Functional Gastrointestinal Disorders
Report from Magnus Simrén, MD, PhD: Irritable Bowel Syndrome: Searching for Underlying Causes
Report from Brennan M. R. Spiegel, MD, MSHS: Diagnostic Testing in Irritable Bowel Syndrome: Theory vs. Reality
Report from Sylvie Bradesi, PhD: Role of the Central Immune System in Functional Disorders
Paul E. Hyman, MD
Report from Miranda A. L. van Tilburg, PhD: Home Based Guided Imagery to Treat Pediatric Functional Abdominal Pain
Report from Fernando Azpiroz, MD, PhD: Understanding Intestinal Gas
2005 Award Recipients
Report from Yvette Tache, PhD: Stress and Irritable Bowel Syndrome: Unraveling the Code
Report from Shaheen Hamdy, MRCP, PhD: Adult Neurogenic Dysphagia -- Disorders and Conditions that Disrupt Swallowing
Report from Michael A. Pezzone, MD, PhD: Chronic Pelvic Pain and the Overlap of Pelvic Pain Disorders
Report from Bridget R. Southwell, PhD: Research into Treatment-Resistant Constipation in Children
Report from Rachel Rosen, MD, MPH: Symptoms Arising from Non-Acid Reflux in Children
2003 Award Recipients
Report from William E. Whitehead, PhD: Summary of Clinical Research Activities
Jyoti N. Sengupta, PhD
Report from Caroline Elder Danda, PhD: Biopsychosocial Perspectives on Assessment and Treatment
Report from Terry Buchmiller-Crair, MD: Using the Fetal Gastrointestinal Tract to Overcome Neonatal Disease
Report from Dan L. Dumitrascu, MD, PhD: The Psychosocial Adjustment to Illness in Irritable Bowel Syndrome
Report from Klaus Bielefeldt, MD, PhD: Understanding Pain and Discomfort in Functional GI Disorders
Research Grants
IFFGD Competitive Grants
2014 IFFGD Idiopathic Gastroparesis Research Grants
Leo Cheng, PhD
Braden Kuo, MD, MSc
Richard McCallum, MD
2008 IFFGD Competitive Research Grants
IFFGD Noncompetitive Grants
Other Research Grant Opportunities
Funding Research
Need for Funding Research
How to Make a Difference
The State of Research at NIH & NIDDK
Clinical Trials & Studies
Guide to Randomized Clinical Trials
Industry Sponsored Clinical Trials and Studies
NIH/Other Sponsored Clinical Trials and Studies

Give Today

give today

Your GIFT can change a life

Your donations help to fund life-changing research and education about chronic digestive conditions and the critical need for improved treatments.

Together, we make a difference.

Donate online